- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
re: AUPH - Aurinia Pharmaceuticals
Posted on 5/16/18 at 9:44 am to bayoubengals88
Posted on 5/16/18 at 9:44 am to bayoubengals88
up 20% on this play. what fun to finally be on the good side of a tun
1
Posted on 5/16/18 at 10:47 am to oklahogjr
Yep. Still wish I had money available to buy more
Posted on 5/16/18 at 10:59 am to bayoubengals88
quote:
You must have shorted at $5.50
That's the only logical explanation.
no sir.
i just took a quick look at earnings and and financials and comparered to rest industry..
(the profit margins and returns on equity were instant turnoffs)
pharmaceuticals just arent my cup of tea...but congrats to all with positions.
looks like 7.7 and then 10.50 are the next price targets..
good luck.
Posted on 5/16/18 at 10:59 am to MSTiger33
quote:I'm fairly content. All I want is to make thirty to forty thousand dollars.
Yep. Still wish I had money available to buy more
Posted on 5/16/18 at 11:01 am to mrgreenpants
quote:I guess my only objection to this is that Aurinia cannot be compared to established companies.
i just took a quick look at earnings and and financials and comparered to rest industry..
It's not established, which is why it's in major growth mode (still only worth about 550 million dollars).
Posted on 5/16/18 at 11:14 am to bayoubengals88
quote:
I guess my only objection to this is that Aurinia cannot be compared to established companies.
fair enough.
everyone has their own style
i like to see increasing earnings...for a min 4-5 quarters
...and then returns of equity, etc in the top 20-25% range
(which may explain why i'd only see large cap pharm on my trading lists)
Posted on 5/16/18 at 11:20 am to mrgreenpants
quote:No chance of this until probably 2021, unless the DES indication proves better than Restasis (they say it will).
i like to see increasing earnings...for a min 4-5 quarters
quote:I'm taking a significant risk. It's not for everyone. If this works out then I can start thinking like you do.
(which may explain why i'd only see large cap pharm on my trading lists)
Posted on 5/16/18 at 11:49 am to bayoubengals88
I had 2000 shares. Sold half this morning at a nice profit. The rest is a core holding waiting for phase 3 results. Will buy more between 4.50 and 5.50 if it has another pullback.
Posted on 5/21/18 at 4:22 pm to jerryc436
bought my first put option this morning for auph. a 7.5 June put
Posted on 5/21/18 at 10:21 pm to oklahogjr
Hope that works out for you .. but that's a pretty big jump for a stock that's not expected to have any news until next year
Posted on 5/21/18 at 10:35 pm to jmcwhrter
quote:
put option
quote:Hmmm.....
Hope that works out for you .. but that's a pretty big jump for a stock that's not expected to have any news until next year
Posted on 5/25/18 at 10:14 am to jerryc436
Been watching this stock for several months. Sold half my position during the pop (hard to not realize that gain), let it fall back and now bought back into a good position. If the news continues to be positive will consider 4/5/6x my position.
Posted on 8/2/18 at 10:18 am to Rendevoustavern
Any updates/thoughts Bayou? Looking to buy back in before earnings next week.
Posted on 8/3/18 at 7:30 am to Caymus
I haven’t paid a lot of attention to it recently.
Earnings report is next Thursday 8/9
I’d expect a loss of course...I’m sure it’s been costly to jumpstart three clinicals recently.
Should have data on the DES drug that is trying to better Restasis by end of this year.
$5 to $5.50 is buy zone for now.
Earnings report is next Thursday 8/9
I’d expect a loss of course...I’m sure it’s been costly to jumpstart three clinicals recently.
Should have data on the DES drug that is trying to better Restasis by end of this year.
$5 to $5.50 is buy zone for now.
Posted on 9/24/18 at 8:21 pm to bayoubengals88
Some updates:
FSGS disease trial and analysis (currently in phase 2)
Michael Goodman's Twitter
FSGS disease trial and analysis (currently in phase 2)
Michael Goodman's Twitter
quote:(Allergan is a multi billion dollar pharma)
I see $AUPH and $RVNC as 2 giant pouncers with the potential to seriously wound $AGN.
quote:
In July, $AUPH started P2 study of a nanomicellar formulation of voclo in ~90 pts w dry eye. Comparator is Restasis; voclo has pot’l for improved dosing schedule & time to onset. ~20 million pts in US. Data by end 2018 or early 2019. AUPH will likely out license this asset
quote:
I like voclo's chances. It has 4x greater concentration of active ingredient than Restasis, potentially more tolerable, better dosing. Let's see what the P2a study shows.
quote:
In June, $AUPH started a PoC study of voclo in 20 pts w FSGS (Focal Segmental Glomerulosclerosis ). As in LN, early redux of proteinurea is critical to LT kidney health. 5,400 pts diagnosed yearly in US. Enrollment should wrap up in 12 mos, w interim data 2019.
This post was edited on 9/24/18 at 8:23 pm
Posted on 9/25/18 at 3:31 pm to bayoubengals88
Phase 3 enrollment completed today (ahead of schedule)
We’re now a year away from data
We took 34 extra enrollees due to high demand.
358 patient study now.
Start your clocks...
We’re now a year away from data
We took 34 extra enrollees due to high demand.
358 patient study now.
Start your clocks...
Posted on 9/25/18 at 3:36 pm to bayoubengals88
Press Release:
Target enrollment has been exceeded and completed ahead of schedule
-Company anticipates primary data analysis in Q4 2019
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries.
“We are elated by the significant interest this trial has garnered around the globe, which reinforces the need for new treatment options for patients living with lupus nephritis,” said Richard M. Glickman, Aurinia’s Chairman and Chief Executive Officer. “I continue to be impressed by the level of dedication exhibited by our team to execute this trial with great diligence and expediency.”
The AURORA clinical trial is a global, double-blind, placebo-controlled study to evaluate whether voclosporin when added to background therapy of mycophenolate mofetil (MMF)/CellCept® can increase speed of and overall renal response rates in the presence of low dose steroids. The primary endpoint for the study is complete renal response at 52 weeks, after which patients can choose to enroll into a 104-week blinded extension study.
“We would like to thank our trial patients, physicians, trial site staff, and advocacy groups for their extraordinary efforts which has led to this result,” said Neil Solomons, M.D., Aurinia’s Chief Medical Officer. “We look forward to sharing the results of the trial in late Q4 2019 and to completing our NDA submission in Q2 2020.”
Target enrollment has been exceeded and completed ahead of schedule
-Company anticipates primary data analysis in Q4 2019
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries.
“We are elated by the significant interest this trial has garnered around the globe, which reinforces the need for new treatment options for patients living with lupus nephritis,” said Richard M. Glickman, Aurinia’s Chairman and Chief Executive Officer. “I continue to be impressed by the level of dedication exhibited by our team to execute this trial with great diligence and expediency.”
The AURORA clinical trial is a global, double-blind, placebo-controlled study to evaluate whether voclosporin when added to background therapy of mycophenolate mofetil (MMF)/CellCept® can increase speed of and overall renal response rates in the presence of low dose steroids. The primary endpoint for the study is complete renal response at 52 weeks, after which patients can choose to enroll into a 104-week blinded extension study.
“We would like to thank our trial patients, physicians, trial site staff, and advocacy groups for their extraordinary efforts which has led to this result,” said Neil Solomons, M.D., Aurinia’s Chief Medical Officer. “We look forward to sharing the results of the trial in late Q4 2019 and to completing our NDA submission in Q2 2020.”
Posted on 9/25/18 at 4:05 pm to bayoubengals88
I've just been holding this. figured as far out as we are there will be some rumor or gossip to drive price up at some point early atleast
Posted on 9/25/18 at 5:18 pm to bayoubengals88
Thanks for the update bengal I’m holding
Page 11 of 164
Popular
Back to top
Follow TigerDroppings for LSU Football News